drugset / Trial / NCT00160680

ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)

NCT00160680 ↗

Phase 4 Completed 62 enrolled UCB Pharma
RandomizedParallel-groupOpen-labelTreatment

Summary

Comparison of clinical efficacy and safety of levocetirizine in PER continuous versus on demand, measured by evolution of individual symptom scores during 6 months.

Timeline

Start
2005-03-01
Primary completion
2006-06-01
Completion
2006-06-01

Outcome

Missed primary endpoint

registry Continuous Treatment (CT) vs On Demand Treatment (ODT); p =0.667 NCT00160680 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Levocetirizine Unknown 5 mg Oral